Quote | Oryzon Genomics S.A. (OTCMKTS:ORYZF)
Last: | $1.41 |
---|---|
Change Percent: | 0.0% |
Open: | $1.41 |
Close: | $1.41 |
High: | $1.41 |
Low: | $1.41 |
Volume: | 300 |
Last Trade Date Time: | 04/16/2024 03:00:00 am |
News | Oryzon Genomics S.A. (OTCMKTS:ORYZF)
All resolutions were approved Additional resolution to increase capital for up to 100 million euros approved 42.6867% of the issued shares represented MADRID and CAMBRIDGE, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a c...
Selected for oral presentation Conference will be held in Milan on September 21-23 MADRID and CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop th...
Message Board Posts | Oryzon Genomics S.A. (OTCMKTS:ORYZF)
Subject | By | Source | When |
---|---|---|---|
Oryzon sube un 40% tras anunciar resultados clnicos | pennystock_es | investorshub | 12/22/2016 4:40:32 PM |
Oryzon recibe 0,74 millones para el desarrollo de | pennystock_es | investorshub | 12/22/2016 4:39:19 PM |
Oryzon Genomics Announces Presentation and Panel Discussion at | pennystock_es | investorshub | 02/17/2016 5:18:21 PM |
Oryzon to Attend the 34th Annual J.P. Morgan | pennystock_es | investorshub | 01/05/2016 4:18:56 PM |
News, Short Squeeze, Breakout and More Instantly...
Oryzon Genomics S.A. Company Name:
ORYZF Stock Symbol:
OTCMKTS Market:
All resolutions were approved Additional resolution to increase capital for up to 100 million euros approved 42.6867% of the issued shares represented MADRID and CAMBRIDGE, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a c...
Selected for oral presentation Conference will be held in Milan on September 21-23 MADRID and CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop th...
Data from the first two cohorts demonstrated that combination of iadademstat plus gilteritinib was safe and showed strong antileukemic activity A third cohort is ongoing following FDA’s OPTIMUS guidance MADRID and CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Oryzon G...